Veracyte Inc VCYT:NASDAQ

Last Price$28.34Cboe Real-Time Last Sale as of 1:13PM ET 6/20/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.01(0.04%)
Bid (Size)$28.31 (100)
Ask (Size)$28.39 (100)
Day Low / High$28.34 - 29.38
Volume230.1 K

View Biotechnology IndustryPeer Comparison as of 06/20/2019


Veracyte Inc ( NASDAQ )

Price: $28.34
Change: +0.01 (0.04%)
Volume: 230.1 K
1:13PM ET 6/20/2019

Alector Inc ( NASDAQ )

Price: $18.32
Change: -0.80 (4.18%)
Volume: 54.8 K
12:33PM ET 6/20/2019

Fate Therapeutics Inc ( NASDAQ )

Price: $19.94
Change: -0.05 (0.25%)
Volume: 356.6 K
1:15PM ET 6/20/2019

Esperion Therapeutics Inc ( NASDAQ )

Price: $50.50
Change: -0.13 (0.26%)
Volume: 103.4 K
1:14PM ET 6/20/2019

Intrexon Corp ( NASDAQ )

Price: $8.35
Change: -0.20 (2.34%)
Volume: 1.3 M
1:14PM ET 6/20/2019

Read more news Recent News

Veracyte Says Cancer Cytopathology Details Co.'s Role in Reducing 'Unnecessary' Surgeries in Thyroid Cancer Diagnosis
2:56PM ET 6/17/2019 MT Newswires

Veracyte (VCYT) said Monday a review article in Cancer Cytopathology, a journal of the American Cancer Society, describes how the technology behind...

Veracyte Seeks $136 Mln From Share Sale at 3.8% Discount for Potential Acquisitions, Debt Payment
8:46AM ET 5/03/2019 MT Newswires

Veracyte Inc. (VCYT) late Thursday said it plans to raise $127.9 million selling 5.5 million shares at $23.25 apiece, or 3.8% below Thursday's close....

Veracyte Prices 5.5 Mln Shares at $23.25 Each in Offering
8:59PM ET 5/02/2019 MT Newswires

Veracyte (VCYT) said it priced 5.5 million shares at $23.25 each in an underwritten public offering. The offering is expected to close on or about May 7....

Veracyte Plans to Sell 5 Mln Shares in Underwritten Public Offering
5:14PM ET 5/01/2019 MT Newswires

Veracyte (VCYT) said it plans to sell 5 million shares in an underwritten public offering and expects to grant the underwriters a 30-day option to purchase...

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Number of Employees270
Recent SEC Filing06/13/20194
Chairman & Chief Executive OfficerBonnie H. Anderson
President & Chief Operating OfficerChristopher M. Hall
Chief Financial OfficerKeith Kennedy
Chief Scientific & Medical OfficerGiulia C. Kennedy

Company Highlights

Price Open$28.82
Previous Close$28.33
52 Week Range$8.77 - 29.38
Market Capitalization$1.2 B
Shares Outstanding41.6 M
SectorHealth Technology
Next Earnings Announcement07/22/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.42
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-15.51%
Return on Equity-23.43%

Analyst Ratings as of 06/07/2019

Consensus RecommendationConsensus Icon
Powered by Factset